Aurobindo Pharma Ltd. (AUROPHARMA)
NSE
1,698.90
+6.90 (+0.41%)
Closed
Sep 9, 2026
Day's Range
1,672.001,704.00
52 wk Range
1,036.001,717.00
Financial Statements - AUROPHARMA - Aurobindo Pharma Ltd.
Revenue
333.84B▲ 6.4%
Net Income
35.02B▲ 0.6%Net Margin 10.5%
EBITDA
74.05B▲ 3.0%
Free Cash Flow
24.21B▲ 72.4%
Income Statement
| Period Ending | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|---|
| Sales | 333.84B | 313.78B | 287.04B | 246.17B | 233.66B | 245.57B |
| Cost of Goods | 143.24B | 137.41B | 132.36B | 118.99B | 108.15B | 106.11B |
| Gross Profit | 190.59B | 176.36B | 154.68B | 127.17B | 125.51B | 139.46B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 51.92B | 50.48B | 43.90B | 25.37B | 33B | 44.76B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 51.11B | 50.66B | 43.79B | 26.12B | 33.72B | 73.43B |
| Income Tax | 16.08B | 15.82B | 12.11B | 6.84B | 7.25B | 20.09B |
| Net Income | 35.02B | 34.83B | 31.68B | 19.27B | 26.47B | 53.33B |
| EPS Basic | 60.34 | 59.81 | 54.16 | 32.9 | 45.19 | 91.05 |
| EPS Diluted | 60.34 | 59.81 | 54.16 | 32.9 | 45.19 | 91.05 |
| Basic Shares Outstanding | 580.80M | 582.87M | 585.93M | 585.93M | 585.93M | 585.93M |
| Diluted Shares Outstanding | 580.80M | 582.87M | 585.93M | 585.93M | 585.93M | 585.93M |
| Ebit | 54.64B | 55.06B | 46.48B | 27.41B | 34.09B | 74.03B |
| Ebitda | 74.05B | 71.89B | 63.76B | 39.96B | 46.52B | 53.78B |
| Net Income Continuous Operations | 51.11B | 50.66B | 43.79B | 26.12B | 33.72B | 73.43B |
| Minority Interests | 17.80M | 23.10M | 40M | -1.50M | 10.40M | 10.20M |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 100K |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
